Search

Displaying results 3101 - 3110 of 8469 in total
  1. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.

  2. Drug

    Sarconeos

    go.drugbank.com/drugs/DB16457
    Investigational

    Sarconeos is an activator of the MAS receptor.

  3. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    Intrinsic factor (IF), also known as gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells of the stomach that is necessary for the absorption of vitamin B12 (cobalamin) later

  4. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342]

  5. Drug

    Tandamine

    go.drugbank.com/drugs/DB09192
    Experimental

    Tandamine was researched in 1970s as an antidepressant but was never commercialized. Tandamine is an analog of pirandamine and it acts as a selective serotonin reuptake inhibitor (SSRI).

  6. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret. … This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including

  7. Drug

    Citrulline

    go.drugbank.com/drugs/DB00155
    InvestigationalNutraceutical

    It is also produced from arginine as a by-product of the reaction catalyzed by NOS family. Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.

  8. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.

  9. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  10. Drug

    Santonin

    go.drugbank.com/drugs/DB19377
    ApprovedWithdrawn

    Santonin is a anthelmintic drug that was previously approved in the US to treat certain parasitic infections.